SCHEMBL2365028

SCHEMBL2365028

CCN1C(C)=C(C(=O)O)C(C)(c2cccc(Cl)c2Cl)C(C(=O)O)=C1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.37
PYGL P06737 6/20 0.36
PYGM P11217 6/20 0.36
NOTUM Q6P988 2/20 0.36
KMT2A Q03164 3/20 0.34
ALDH1A1 P00352 2/20 0.34
GAA P10253 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
CYP2C9 P11712 3/20 0.34
KDM4E B2RXH2 2/20 0.34
MEN1 O00255 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2C19 P33261 2/20 0.34
HIF1A Q16665 2/20 0.34
HSD17B10 Q99714 2/20 0.34
LMNA P02545 2/20 0.34
HPGD P15428 1/20 0.34
TP53 P04637 1/20 0.34
CYP2D6 P10635 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4758577 0.86 TSHR (0.36) TSHRPYGLPYGMNOTUMKMT2A
SCHEMBL7424308 0.85 ALDH1A1 (0.38) TSHRPYGLPYGMNOTUMKMT2A
SCHEMBL7418565 0.84 CYP2C9 (0.33) TSHRPYGLPYGMNOTUMKMT2A
SCHEMBL4884972 0.83 ABCB11 (0.42) TSHRNOTUMKMT2AALDH1A1GAA
SCHEMBL4758583 0.77 PYGL (0.38) TSHRPYGLPYGMNOTUMKMT2A
SCHEMBL30516327 0.75 PYGL (0.34) PYGLPYGMABCB11ABCB1ADORA3
SCHEMBL30656597 0.74 HTR1A (0.39) PYGLPYGMCYP3A4NR1I2ABCB11
SCHEMBL9101372 0.74 TSHR (0.37) TSHRNOTUMKMT2AALDH1A1GAA
SCHEMBL4758043 0.73 CRHBP (0.40) NOTUMKMT2AALDH1A1GAAL3MBTL1
SCHEMBL30516333 0.71 PYGL (0.32) PYGLPYGM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0163237-A2 Di- and tri-peptidal renin inhibitors MERCK & CO. INC. (US) 1985-12-04 EP claimed
EP-3203840-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2017-08-16 EP disclosed
WO-2016057572-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MILLER MARK THOMAS (US) 2016-04-14 WO disclosed
EP-2355830-A1 COMPOSITIONS COMPRISING A CALCIUM CHANNEL BLOCKER OR A CALMODULIN BLOCKER FOR USE IN THE REMOVAL OF HYPERPLASTIC SKIN LESIONS Adams, Kenneth W. (CA) 2011-08-17 EP disclosed
WO-2010048722-A1 COMPOSITIONS COMPRISING A CALCIUM CHANNEL BLOCKER OR A CALMODULIN BLOCKER FOR USE IN THE REMOVAL OF HYPERPLASTIC SKIN LESIONS ADAMS KENNETH W (CA) 2010-05-06 WO disclosed
WO-2010027113-A2 PROCESS FOR PREPARING (S)-(-)-FELODIPINE AHN-GOOK PHARMACEUTICAL CO., LTD (KR) 2010-03-11 WO disclosed
EP-1613591-A1 PROCESS TO PREPARE 1,4-DIHYDROPYRIDINE INTERMEDIATES AND DERIVATIVES THEREOF Apotex Pharmachem Inc. (CA) 2006-01-11 EP disclosed
WO-2004089902-A1 PROCESS TO PREPARE 1,4-DIHYDROPYRIDINE INTERMEDIATES AND DERIVATIVES THEREOF APOTEX PHARMACHEM INC. (CA) 2004-10-21 WO disclosed
WO-2001092283-A2 COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2001-12-06 WO disclosed
EP-0850046-A2 MICROEMULSIONS FOR USE AS VEHICLES FOR ADMINISTRATION OF ACTIVE COMPOUNDS Astra Aktiebolag (SE) 1998-07-01 EP disclosed
WO-1997009964-A1 MICROEMULSIONS FOR USE AS VEHICLES FOR ADMINISTRATION OF ACTIVE COMPOUNDS ASTRA AKTIEBOLAG (SE) 1997-03-20 WO disclosed